In conclusion, we show here in a relatively large breast carcinoma patient group that MMP-2 immunoreactive protein is an independent prognostic indicator that might prove valuable in certain subgroups, such as patients with a receptor-negative breast carcinoma. The gene discussed is MMP2; the disease is breast carcinoma.